This article is a collection of STAT Plus newsletter headlines that highlights the competitive landscape of obesity drugs. It references the development of triple hormone receptor agonists and monthly formulations for obesity treatment. The content also covers the latest data and news regarding GLP-1 receptor agonists presented at the American Diabetes Association (ADA) conference.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.